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Abstract
Background: Several cases of Burkholderia pseudomallei infection in CF have been previously reported. We aimed
to identify all cases globally, risk factors for acquisition, clinical consequences, and optimal treatment strategies.
Methods: We performed a literature search to identify all published cases of B. pseudomallei infection in CF. In
addition we hand-searched respiratory journals, and contacted experts in infectious diseases and CF around the
world. Supervising clinicians for identified cases were contacted and contemporaneous clinical data was requested.
Results: 25 culture-confirmed cases were identified. The median age at acquisition was 21 years, mean FEV1 %
predicted was 60 %, and mean BMI was 19.5 kg/m2. The location of acquisition was northern Australia or south-east
Asia for most. 19 patients (76 %) developed chronic infection, which was usually associated with clinical decline.
Successful eradication strategies included a minimum of two weeks of intravenous ceftazidime, followed by a
consolidation phase with trimethoprim/sulfamethoxazole, and this resulted in a higher chance of success when
instituted early. Three cases of lung transplantation have been recorded in the setting of chronic B. pseudomallei
infection.
Conclusion: Chronic carriage of B. pseudomallei in patients with CF appears common after infection, in contrast to
the non-CF population. This is often associated with an accelerated clinical decline. Lung transplantation has been
performed in select cases of chronic B. pseudomallei infection.
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Background
Burkholderia pseudomallei is a gram-negative environ-
mental bacterium found in soil and surface water that
causes melioidosis, which most commonly occurs in
south-east Asia and northern Australia [1]. Melioidosis
has been increasingly recognised to occur in diverse
tropical locations globally, including the Americas and
Africa [2]. B. pseudomallei is now classified by the US
CDC as a tier-1 select agent because of its aerosolized
biothreat potential (http://www.selectagents.gov/). Infec-
tion can occur through inhalation, aspiration and inges-
tion, although transmission most commonly occurs via
percutaneous inoculation [3]. Pneumonia is the most
common clinical manifestation (presumably via haema-
togenous spread to the lungs), with a spectrum including
mild self-limiting infection, subacute pulmonary disease
mimicking tuberculosis, rapidly progressive multifocal
pneumonia and systemic sepsis which confers a high
mortality of over 50 % [4]. Melioidosis is often reported in
people returning to their home country after travelling to
an endemic region. At-risk tourists include those with
diabetes and cystic fibrosis (CF) exposed to soil and sur-
face water or monsoonal storms where aerosolization of
B. pseudomallei may occur [1, 2].
Generally patients who survive infection clear the
organism and rarely relapse following an adequate dur-
ation of therapy [5]. In the 25-year Darwin Prospective
Melioidosis Study [6], only one of over 750 consecutive
melioidosis patients had evidence of long-term persist-
ing infection with B. pseudomallei. This patient with
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non-CF bronchiectasis has continued to have positive
sputum culture results for B. pseudomallei 14 years
after diagnosis and treatment of melioidosis. Whole
genome sequencing of isolates obtained from this
patient over a 12-year period demonstrates loss of viru-
lence and immunogenic factors, as well as deletion of
pathways involved in environmental survival [7]. There
have been a number of published case reports of
patients with CF who have acquired B. pseudomallei
infection and a number of these cases have demon-
strated chronic carriage of B. pseudomallei in patients
with CF [8–17].
In this study, we aimed to describe the international
experience of infection with B. pseudomallei in patients
with CF. We have examined potential risk factors for
acquisition and persistence of infection, summarised glo-
bal experience of effective antibiotic strategies, and
assessed the long-term clinical sequelae of infection.
Methods
The study was conducted in accordance with the amended
Declaration of Helsinki, and was approved by the local
human research ethics committee. (Metro North Hospital
and Health Service Human Research Ethics Committee,
Queensland, HREC/13/QPCH/51). A literature search
(utilising Medline, Embase, CINAHL, AustHealth and
ScienceDirect databases and by Google Scholar) was per-
formed to identify all published cases of B. pseudomallei
infection in patients with CF in July 2013 and repeated in
August 2014 (Additional file 1). Case reports were hand-
searched and clinicians from European, North American,
and Australasian CF centres that had either reported B.
pseudomallei in CF patients, or were experts from CF
microbiology laboratories, were contacted to locate add-
itional cases not previously reported. Data entry sheets
were provided to the clinicians that had supervised the care
of the identified cases, and results including contemporan-
eous clinical metrics were compiled (Additional file 2).
Where supervising clinicians could not be contacted,
information was extracted from the published reports
[8, 9, 11, 14]. Chronic infection was defined as persist-
ent cultures of B. pseudomallei from sputa or endo-
bronchial washings for 12 months or more.
Results
Case identification
Twenty-five culture-proven cases between 1987 and 2015
were identified (Table 1). 16 cases were identified by litera-
ture search. A further nine cases were identified through
international consultation with experts of CF and infec-
tious disease that had experience in the diagnosis and
management of B. pseudomallei infection. Of the 25 cases,
detailed clinical data were made available by the treating
clinicians for 21 cases, and in the remaining four cases
details were extracted from published reports. An add-
itional two cases were identified where melioidosis was
suspected based on positive B. pseudomallei serology, al-
though culture confirmation was elusive. Both cases died
from progressive refractory respiratory infection after
being presumptively infected while travelling overseas;
these cases were not included further in this analysis.
Three additional possible cases from Mexico were identi-
fied through hand-searching references of published arti-
cles [18]. There were insufficient data available and the
accuracy of bacterial identification was uncertain, there-
fore these cases were also excluded.
Epidemiology and risk factors for B. Pseudomallei
acquisition
Of the 25 cases, 15 (62.5 %) were males, and ten females.
The median age at acquisition was 21 years (range 7–38
years). The presumptive location of acquisition for the
majority was either northern Australia or South-east Asia.
There was one case each of presumed acquisition in
Brazil, Aruba and the British Virgin Islands, respectively.
The mean forced expiratory volume in 1 s (FEV1) was
60 % predicted (range 38-107 %) and mean body mass
index (BMI) was 19.5 kg/m2 (range 13–24). Two cases
were siblings. Specific Cystic Fibrosis Transmembrane
Conductance Regulator (CFTR) mutations were docu-
mented in 17 of the 25 patients. Of these, 47 % (8) were
F508del homozygotes and 35 % (6) were F508del hetero-
zygotes. Having CF (pulmonary disease) was the apparent
major risk factor in all patients. Of the 19 patients where
data were available, CF-related diabetes was present in
three (16 %) and there was impaired glucose tolerance in
one. Other common risk factors for infection with B. pseu-
domallei such as hazardous alcohol use, chronic renal dis-
ease, congestive cardiac failure, rheumatic heart disease
and immunosuppressive therapy were not reported in any
of the cases.
Clinical and radiological manifestations of infection with
B. Pseudomallei
Of the 25 patients, clinical manifestations at the pre-
sumed time of acquisition were available in 24. In ten
(42 %), isolation of B. pseudomallei was an incidental
finding on routine sputum surveillance and in the
remaining 14 patients (61 %), isolation of B. pseudo-
mallei was associated with symptoms of increased
cough and sputum. Systemic features (either one or a
combination of the following: fever, weight loss or de-
teriorating glycemic control) were reported in 10 pa-
tients. New radiological changes were documented in
eight patients, with patchy areas of consolidation be-
ing the most common abnormality reported. Lobar
consolidation, progressive lobar destruction, increased
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Table 1 Cases of culture confirmed B. pseudomallei infection in CF
Patient Year isolated Location of
acquisition
Country of
residence
Age Gender CFTR Mutation FEV1% BMI Co-pathogens ETOH >40 g daily Diabetes
1 (O’Carroll, 2003) [12] 1987 Northern Australia Australia 21 M F508del/F508del 49 21 Pseud No No
2 Early 1990’s Northern Australia Australia 40 M F508del/R117 44.5 23 Pseud Yes No
Mycobacterium
intracellulare
3 (Schülin, 2001) [14] 1992 Likely Thailand Germany 31 M Unknown Unknown Unknown Unknown Unknown Unknown
4 (Visca, 2001) [15] 1998 South-East Asia Italy 25 F Unknown Unknown Unknown Pseud Unknown Unknown
BCp
5 (Dance, 1999) [11] 1998 Malaysia England 20 M Unknown Unknown Unknown Unknown Unknown Unknown
6 (Holland, 2002) [16] 1999 Northern Australia New Zealand 8.5 M G551D/1717-16 > A 46 15 Pseud No No
Aspergillus fumigatus
7 (Holland, 2002) [16] 2000 Northern Australia New Zealand 7 F G551D/1717-16 > A Unknown 19 Haemophilus
influenzae
No No
Staph A
8 (O’Carroll, 2003) [12] 2000 Northern Australia Australia 21 M F508del/F508del 35 22 Pseud No Yes
Staph A
BCp
9a (Holland, 2002) [16] 2000 Northern Australia Australia 18 M F508del/F508del 45 21 Pseud Yes No
Staph A
BGl
Mycobacterium
intracellulare
Other
10 (O’Carroll, 2003) [12] 2001 Northern Australia Australia 14 M F508del/G542X 80 17 Pseud No No
Staph
11 (Holland, 2002) [16] 2001 Northern Australia New Zealand 38 M F508del/F508del 36 19 Pseud No IFG
Staph A
12 (O’Carroll, 2003) [12] 2001 Northern Australia Australia 25 F Unknown 80 20 Pseud No No
Staph A
BCp
13 (Asiah, 2006) [8] 2004 Malaysia Malaysia 17 M Unknown Unknown Unknown Pseud Unknown Unknown
Staph A
14 (Barth, 2007) [9] 2005 Brazil Brazil 17 F Unknown Unknown Unknown Pseud Unknown Unknown
Staph A
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Table 1 Cases of culture confirmed B. pseudomallei infection in CF (Continued)
15 2005 Thailand England 30 F Unknown 56 21 Pseud No Yes
Staph A
Aspergillus fumigatus
16 (Corral, 2008) [10] 2006 British Virgin Islands England 17 M F508del/E60X 63 22 Pseud Unknown No
Staph ACanada
17 2007 Northern Australia Australia 38 M F508del/F711 + 5G > A 29 19 Pseud No No
Staph A
Aspergillus terreus
18 2007 Thailand New Zealand 10 F F508del/17aa + IG74 107 16 Pseud No No
Staph A
Other
19 2008 Thailand Australia 22 F F508del/F508del 85 23 Pseud Yes Yes
20 (O’Sullivan, 2011) [13] 2009 Aruba USA 7 F F508del/F508del 88 13 None No No
21 2010 Vietnam/Cambodia England 23 F F508del/F508del 44 19 Pseud No No
Haemophilus
influenzae
22 (Radhakrishna, 2014) [17] 2011 Thailand Australia 25 M Unknown 95 24 Pseud Unknown No
Aspergillus fumigatus
23 2012 Malaysia/Philippines Malaysia 19 M R553X/unknown 18 17 Pseud No No
24 2013 Thailand/Japan England 30 M F508del/E60X 67 23 Pseud No No
25 2015 Thailand England 21 F F508del/F508del 71 18 Pseud No No
Staph A
Pseud Pseudomona aeruginosa, Staph A Staphylococcus aureus, BCp Burkholderia cepacia complex, BGl Burkholderia gladioli, IFG impaired fasting glucos
a3 distinct B. pseudomallei infections were recorded in this patient over 8 years
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bronchiolectasis with “tree-in-bud” opacities and pro-
gressive bronchiectasis were also reported.
Long-term outcomes following infection with B.
Pseudomallei
In five patients, acquisition of B. pseudomallei did not
result in chronic infection (≥12 months). In one of these
patients (patient 9), there were three different B. pseudo-
mallei infections over an eight-year period, each with
distinct organisms as confirmed by multilocus sequence
typing, [6] and each episode was successfully cleared with
2 to 3 week courses of intravenous ceftazidime and oral
trimethoprim/sulfamethoxazole (TMP/SMX) followed by
consolidation with three months of oral TMP/SMX. This
case was considered to have been infected with distinct B.
pseudomallei strains on three occasions [6]. Two patients
presented with acute pneumonia and the organism was
eradicated after a combination of intravenous followed by
consolidation nebulized and oral antibiotics (patient 16
and 20). One further patient who was not unwell at the
time of isolation of the organism spontaneously cleared
the infection without specific antibiotics directed at B.
pseudomallei (patient 19).
In 19 patients (79 %), initial infection was followed by
evidence of chronic infection (range 1 – 11 years)
(Table 2). Of these patients, 14 were thought to have had
an accelerated decline in pulmonary status by their phys-
ician, although in one case the reported decline occurred
after a four-year period of clinical stability despite evi-
dence of persistent infection. Markers of clinical deterior-
ation that were reported included increased exacerbation
frequency, reduced response to intravenous antibiotics
and an accelerated decline in lung function. Six patients
had died by August 2014, between two and six years after
the first isolation of B. pseudomallei (patients 6, 7, 8, 11,
15 and 18). In two, septicemia was documented and
complicated by respiratory failure and death (patients
7 and 15). In one recurrent bacteraemia occurred and
oral corticosteroids appeared to precipitate an episode
(patient 15). Tigecycline controlled bacteremia despite
progressive resistance to TMP/SMX and ceftazidime.
In five patients, evidence of chronic infection (duration
5–17 years) was not associated with clinical deterior-
ation (patients 1, 2, 10, 17 and 22).
In one patient duration of infection and outcome was
unknown (patient 5), and another one patient was iden-
tified shortly prior to publication (patient 25). Initial
sputa have been clear after three weeks of intravenous
antibiotics. The patient continues on suppressive oral
antibiotics, and long term outcomes are awaited.
Eradication strategies
Specific eradication strategies were documented in 19
of the 25 patients. Six patients (including patient 9 -
multiple episodes of infection) achieved clearance of B.
pseudomallei. Eradication attempts were unsuccessful
in 11 patients and there was an unknown outcome in
two patients (patient 24, patient 25, Table 3). For cases
of successful eradication, the period of known infection
was usually less than 12 months, whereas failed eradica-
tion usually occurred where long-term infection was evi-
dent. Ceftazidime was a key component of induction
therapy in all but one of the patients with successful eradi-
cation, and all had consolidation therapy from one to four
months after completion of intravenous antibiotics and in
most cases, oral TMP/SMX was used. In select cases, anti-
biotic regimens also included combinations of oral amoxi-
cillin/clavulanic acid, doxycycline and chloramphenicol,
and nebulized meropenem (250–500 mg twice daily in
4 ml of sterile water).
Two patients spontaneously cleared infection without
specific eradication strategies (patients 2 and 19)
(Table 2). Whilst not a formal approach at eradication of
B. pseudomallei, patient 12 was treated with 3-week
courses of ceftazidime, meropenem and tobramycin over
a 15-month period for repeated episodes of pneumonia,
after which time B. pseudomallei was no longer cultured
from sputum.
Transplantation with B. pseudomallei
Transplantation was considered for six patients but two
patients were not listed due to concerns about the po-
tential risk of B. pseudomallei graft infection after trans-
plantation (patient 15, patient 18). One patient was
listed for transplant but deteriorated very rapidly and
died several months later without transplant (patient 8).
Three patients have undergone lung transplants
(patients 1, 11 and 21) and immediate post-transplant
results have been satisfactory. One patient (patient 1) re-
mains well 10 years post-transplant with normal lung
function despite endobronchial washings remaining
positive for B. pseudomallei; another patient (patient 12)
died five years after transplantation, and post-transplant
endobronchial washings were positive; and the third pa-
tient (patient 21) is alive two years after transplantation
also with B. pseudomallei recurrently isolated from post-
transplant respiratory samples. Chronic B. pseudomallei
suppression has been used in all cases (either TMP/
SMX or doxycycline).
Discussion
CF is a disease that predominates in people of Caucasian
descent and most patients do not live in tropical or sub-
tropical regions where B. pseudomallei is endemic. As sur-
vival has increased, CF patients have increasingly had the
opportunity to travel, and as a consequence over the past
two decades there have been a number of reports of infec-
tion with B. pseudomallei in CF patients [8–17].
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We have identified 25 cases of B. pseudomallei in CF
patients and the vast majority of CF patients who have
become infected with B. pseudomallei have acquired the
organism through travel to endemic areas such as
Southeast Asia and northern Australia. Most patients
already had significant structural lung disease and low
BMI, which suggests these factors are likely to be im-
portant risk factors for acquisition of the organism in
CF. However severe CF disease per se was not an obvi-
ous prerequisite for acquisition. Some patients were also
diabetic but other risk factors for melioidosis such as
hazardous alcohol use, chronic renal disease, heart dis-
ease and immunosuppressive therapy were not present
in this cohort.
In contrast with the general population, acquisition of B.
pseudomallei in CF appeared to be more likely to result in
chronic infection, which is problematic given how difficult
it can be to eradicate this pathogen even with targeted
antimicrobial therapy. Whilst the clinical manifestations
of infection were varied in the CF patients, and a chronic
Table 2 Cases of chronic infection
Patient Duration of
infection
Year of
acquisition
Eradication
attempted
Eradication
successful
Outcome
1 (O’Carroll, 2003) [12] >15 years 1987 No N/A Slow decline in lung health consistent with CF;
transplant 2004
10 (O’Carroll, 2003) [12] 11 years 2001 No N/A Slow decline in lung health consistent with CF
3 (Schülin, 2001) [14] >9 years 1992 Yes No Increased frequency of exacerbations
15 >8 years 2005 Yes No Accelerated decline; transplant declined due to
B. pseudomallei infection; B. pseudomallei
septicaemia;a died 2009
22 (Radhakrishna, 2014) [17] 7 years 2011 Yes Yes No obvious clinical impact
2 7 years Early 1990’s No N/A Spontaneously clearance of infection after approx.
7 years; 11 years later died of neutropenic sepsis
complicating treatment of Duke’s C colon cancer.
7 (Holland, 2002) [16] >6 years 2000 Yes No Accelerated decline with increased frequency of
exacerbations; B. pseudomallei septicaemia; died 2009
17 6 years 2007 No N/A Slow decline in lung health consistent with CF
18 6 years 2007 Yes No Accelerated decline; transplant declined due to
B. pseudomallei; died 2013
11 (Holland, 2002) [15] 5 years 2001 Yes No Accelerated decline; transplant 2006; died 2011
23 >12 months 2012 Yes No Progressive destruction right upper lobe
6 (Holland, 2002) [16] >4 years 1999 Yes No After presumed latency of 4 years developed
accelerated decline with pneumonia; died 2004
24 4 years 2009 Yes Unknown Fall in lung function; stable after targeted
antimicrobial therapy
14 (Barth, 2007) [9] >2 years 2005 Yes No Accelerated decline with rapid decrease in lung
function and recurrent exacerbations over 2 years;
long term outcome unknown
8 (O’Carroll, 2003) [12] 2 years 2000 Yes No Rapid decline post infection; died 2 years after
initial infection
21 2 years 2010 Yes No Accelerated decline; transplant 2012 with persistent
infection post-transplant
12 (O’Carroll, 2003) [12] 2 years 2001 Yes Yes Repeated admissions with pneumonia, treated
with 3 week courses of ceftazidime, meropenem,
tobramycin; infection ultimately spontaneously
cleared
4 (Visca, 2001) [15] 1 year 1998 Yes Yes Deteriorating pulmonary sepsis, increasingly
refractory to anti-pseudomonal antibiotics;
cleared infection with antimicrobial therapy;
still alive 2013
13 (Asiah, 2006) [8] 1 year 2004 Yes Yes Increased pulmonary sepsis during infection with
B. pseudomallei; remained well 5 months after
completing targeted anti-microbial therapy
aRecurrent episodes of B. pseudomallei bacteremia
bIn patient 5 the duration of infection and long term outcome was unknown
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Table 3 Eradication strategies
Patient Duration of infection
prior to treatment
Induction Consolidation
Treatment Duration Treatment Duration
Successful eradication
16 (Corral, 2008)
[10]
Unknown – lived
in BVI
Meropenem 2 g tds 19 days TMP/SMX 960 mg bd 19 days
Minocycline 100 mg bdMinocycline 100 mg bd
Tobramycin (neb)a 80 mg bd
20 (O’Sullivan, 2011) [13] 3 months Imipenem 14 days Meropenem (neb) 28 days
Ceftazidime TMP/SMX 960 mg bd 2 years
4 (Visca, 2001) [15] 12 months Ceftazidime 42 days TMP/SMX 960 mg bd 210 days
TMP/SMX 960 mg bd Doxycycline
Chloramphenicol
13 (Asiah, 2006) [8] 12 months Ceftazidime 56 days TMP/SMX 960 mg bd 112 days
TMP/SMX 960 mg bd Doxycycline
22 (Radhakrishna, 2014) [17] 7 years Meropenem 2 g tds Approx 56 days Doxycycline followed by
amoxycillin/clavulanic acid
(doxycycline allergy)
12 months
Ceftazidime 3 g tds
Tobramycin (neb) 80 mg bd
TMP/SMX 960 mg bd
9 (Holland, 2002) [16] Infection 1 Unknown Ceftazidime 14 days TMP/SMX 960 mg bd 90 days
TMP/SMX 960 mg bd
9 (Holland, 2002) [16] Infection 2 1 month Ceftazidime 21 days TMP/SMX 960 mg bd 90 days
TMP/SMX 960 mg bd
9 (Holland, 2002) [16] Infection 3 1-2 months Ceftazidime 14 days TMP/SMX 960 mg bd 90 days
TMP/SMX 960 mg bd
Failed Eradication
8 (O’Carroll, 2003) [12] 4 months Meropenem 2 g tds 56 days None
Ceftazidime 3 g tds
17 6-12 months Ceftazidime 3 g tds 14 days TMP/SMX 960 mg bd 84 days
TMP/SMX 960 mg bd
23 >10 months Ceftazidime 3 g tds 21 days Unknown (patient moved
to Malaysia)
TMP/SMX 960 mg bd
Tobramycin 5 mg/kg
3 (Schülin, 2001)
[14]
6 years Unspecified antipseudomonal
antibiotics
14 days No (exacerbations directed
against PsA)
14 (Barth, 2007)
[9]
>18 months Pipracillin/clavulanate 21 days Meropenem 2 g tds 21 days
Tobramycin 5 mg/kg Ceftazidime 3 g tds
Amikacin
TMP/SMX 960 mg bd
15 >8 years Meropenem 2 g tds 14 days TMP/SMX 960 mg bd 126 days
Tobramycin Minocycline 100 mg bd
Meropenem (neb)
18 (1st attempt) 2 months Ceftazidime 1.5 g tds 14 days Infection not cleared therefore
2nd course of IV antibiotics
Tobramycin 300 mg
Amoxycillin/Clavulanic
acid 900 mg
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quiescent disease state can obviously occur, the establish-
ment of chronic infection in most patients usually her-
alded further clinical deterioration, with progressively
refractory bronchopulmonary sepsis being a common fea-
ture. Delayed diagnosis may contribute to chronic infec-
tion and early attempts to eradicate are recommended.
This requires expeditious recognition of the infection in
travellers returning from endemic areas. The identification
of B. pseudomallei can be challenging, and it is possible
that isolates may be confused with other more common
CF pathogens including other Burkholderia species, par-
ticularly if laboratories are not familiar with in vitro char-
acteristics of B. pseudomallei [8, 14, 15]. Furthermore,
infection with B. pseudomallei does not always result in
immediate onset of symptoms as it often would in patients
without CF, and symptoms may masquerade as those typ-
ical of pulmonary exacerbation. It is therefore important
that CF clinicians have a high index of suspicion for pa-
tients returning from endemic areas.
Whilst not universally successful, approaches that util-
ise a 2–3 week course of parenteral ceftazidime, followed
by a 3-month consolidation course of oral.
TMP/SMX, appear to be the most effective. This ap-
proach is similar to that recommended for melioidosis
therapy [1, 2, 19]. If initial response does not successfully
result in persistently negative sputum cultures for B. pseu-
domallei, then a longer course of parenteral ceftazidime
or meropenem (≥4 weeks) should be considered [2]. If pa-
tients are allergic to or intolerant of TMP/SMX, consoli-
dation with several months of doxycycline or amoxycillin/
clavulanic acid have also been successfully used. When
eradication is not possible, and a progressive decline in
health ensues, lung transplantation may be considered. To
date, early post-transplant outcomes have been acceptable
despite persistence of B. pseudomallei.
This case series has several limitations. Firstly, it is likely
other cases have not been identified, either because they
have not been reported, or the infection was not recog-
nised. For example, we excluded three possible cases from
Mexico because of insufficient details [18]. Secondly, out-
comes were not available for some patients, we were unable
to access data (patients 5, 13 and 14), or cases lost to
follow-up (patients 16 and 23). Interestingly, two patients
were reported by two CF centres, by two UK-based centres,
and by centres in the UK and Canada, respectively (patients
15 and 16). After further investigation we noted they were
the same persons, highlighting the mobility of CF patients.
Conclusion
The international experience with B. pseudomallei
described here demonstrates that this organism has the
potential to exhibit novel behaviours in the CF host,
including the development of chronic infection. Further
analysis of B. pseudomallei isolates from those CF patients
with persisting infection may inform on the key mecha-
nisms contributing to bacterial persistence [7]. As a result
of this analysis suggest the following recommendations:
1. Clinicians should have a high index of suspicion for
B. pseudomallei infection for CF patients living in or
returning from areas where it is endemic. Suspicion
should be heightened when fever and or pneumonia
Table 3 Eradication strategies (Continued)
18 (2nd attempt) 2 months Meropenem 84 days TMP/SMX 960 mg bd Long term
Ceftazidime Doxycycline
Amoxycillin/Clavulanic acid
6 (Holland, 2002) [16] >4 years Ceftazidime 50 mg/kg 120 days None (exacerbations directed
against B. pseudomallei)
Piperacillin 50 mg/kg
Amoxycillin/Clavulanic acid
7 (Holland, 2002) [16] >5 years TMP/SMX 960 mg bd 4 years
1st isolation
7 (Holland, 2002) [16] >9 years Imipenem 20 days TMP/SMX 960 mg bd 19 days
2nd isolation Piperacillin/Clavulanic acid 42 days Tetracycline 30 days
Meropenem/TMP/SMX >30 days
11 (Holland, 2002) [16] 3 months Ceftazidime 14 days TMP/SMX 960 mg bd 330 days
Tobramycin
21 1 month Meropenem 2 g tds 42 days Tobramycin (neb) 300 mg bd 42 days
Ceftazidime 3 g tds TMP/SMX 960 mg bd
Tobramycin 7 mg/kg
Success of eradication for patient 24 and patient 25 unknown
aneb = nebulized
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occurs. Close liaison with the CF microbiology
laboratory is important.
2. Eradication of B. pseudomallei infection should be
attempted for CF patients when this pathogen is
first isolated.
3. Initial intravenous therapy should include a
minimum of two weeks intravenous ceftazidime
(and or meropenem if severe sepsis). Consideration
should be given to extending the duration of
intravenous in those CF patients who are
persistently culture-positive on therapy. We also
recommend addition of oral/intravenous TMP/SMX
from the onset of therapy and this should continue
where possible for three months, with regular
clinical monitoring for potential adverse effects
including renal and hepatic dysfuntion, bone marrow
toxicity and potentially life-threatening skin reactions
including DRESS syndrome (drug reaction with
eosinophilia and systemic symptoms).
4. Travel should be avoided to northern Australia or
south-east Asia during the monsoonal season, with
particular care to minimise exposure to wet season
soils and rain in resident patients [20].
5. Person-to-person transmission of B. pseudomallei is
generally thought not to occur. However one case of
siblings who developed infection with identical
strains raises the possibility of cross-infection in CF
and should carefully consider the risks and benefits
of segregation of patients who have isolated this
organism.
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Summary At A Glance: We confirmed that Burkholderia pseudomallei
commonly behaves in novel ways in the CF host, frequently establishing
chronic infection, which often results in poor long-term outcomes.
Eradication should be attempted early where possible, but if unsuccessful,
transplantation can be carefully considered despite chronic infection.
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